Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,680,000 shares, a decrease of 34.4% from the February 28th total of 2,560,000 shares. Currently, 3.7% of the shares of the company are sold short. Based on an average daily volume of 540,400 shares, the days-to-cover ratio is currently 3.1 days.

Insider Buying and Selling at Generation Bio

In related news, Director Anthony G. Quinn acquired 85,000 shares of the stock in a transaction on Monday, January 13th. The shares were acquired at an average price of $0.97 per share, with a total value of $82,450.00. Following the completion of the transaction, the director now owns 299,286 shares in the company, valued at approximately $290,307.42. The trade was a 39.67 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 21.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GBIO. State Street Corp boosted its position in shares of Generation Bio by 1.2% during the third quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after buying an additional 11,669 shares during the last quarter. Baker BROS. Advisors LP raised its stake in Generation Bio by 61.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock worth $4,804,000 after acquiring an additional 737,988 shares during the period. Barclays PLC lifted its position in shares of Generation Bio by 165.5% in the third quarter. Barclays PLC now owns 76,430 shares of the company’s stock valued at $189,000 after acquiring an additional 47,639 shares in the last quarter. FMR LLC boosted its stake in Generation Bio by 0.3% in the 3rd quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after purchasing an additional 15,656 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new position in Generation Bio during the fourth quarter valued at $2,398,000. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Generation Bio Price Performance

Shares of GBIO traded down $0.03 during midday trading on Friday, hitting $0.43. 558,689 shares of the company traded hands, compared to its average volume of 257,951. Generation Bio has a one year low of $0.41 and a one year high of $4.65. The firm has a market cap of $28.67 million, a P/E ratio of -0.20 and a beta of 2.72. The stock has a 50-day moving average of $0.65 and a 200-day moving average of $1.39.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Wednesday, March 19th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The company had revenue of $4.19 million during the quarter, compared to analysts’ expectations of $2.92 million. Sell-side analysts forecast that Generation Bio will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GBIO has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Generation Bio in a report on Friday, March 14th. Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research note on Friday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 price target on shares of Generation Bio in a research note on Monday, March 17th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.